The Cooper Companies, Inc. $COO Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC trimmed its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 0.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 107,258 shares of the medical device company’s stock after selling 173 shares during the quarter. Nisa Investment Advisors LLC owned 0.05% of Cooper Companies worth $7,632,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Zions Bancorporation National Association UT acquired a new stake in shares of Cooper Companies during the 1st quarter worth about $33,000. GKV Capital Management Co. Inc. acquired a new position in Cooper Companies in the 1st quarter valued at about $40,000. J.Safra Asset Management Corp grew its position in Cooper Companies by 204.8% in the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after acquiring an additional 340 shares in the last quarter. Larson Financial Group LLC grew its position in Cooper Companies by 1,071.0% in the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock valued at $61,000 after acquiring an additional 664 shares in the last quarter. Finally, HM Payson & Co. grew its position in Cooper Companies by 147.4% in the 1st quarter. HM Payson & Co. now owns 893 shares of the medical device company’s stock valued at $75,000 after acquiring an additional 532 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Trading Down 0.9%

COO opened at $72.85 on Tuesday. The firm has a market cap of $14.48 billion, a price-to-earnings ratio of 35.89, a price-to-earnings-growth ratio of 1.93 and a beta of 1.02. The Cooper Companies, Inc. has a 52 week low of $61.78 and a 52 week high of $108.01. The business’s 50 day moving average is $69.66 and its two-hundred day moving average is $73.18. The company has a quick ratio of 1.24, a current ratio of 2.12 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.07 by $0.03. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The firm’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, research analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies announced that its board has approved a share buyback program on Wednesday, September 17th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

COO has been the subject of several research reports. BNP Paribas Exane raised Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 target price for the company in a research report on Tuesday, July 22nd. The Goldman Sachs Group set a $64.00 target price on Cooper Companies and gave the company a “sell” rating in a research report on Wednesday, October 1st. Robert W. Baird dropped their target price on Cooper Companies from $97.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, August 28th. Wall Street Zen downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, July 12th. Finally, BNP Paribas raised Cooper Companies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $84.77.

Insider Activity

In other news, COO Gerard H. Warner III bought 1,450 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were bought at an average cost of $69.23 per share, for a total transaction of $100,383.50. Following the completion of the transaction, the chief operating officer owned 18,319 shares in the company, valued at $1,268,224.37. This trade represents a 8.60% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence Erik Kurzius bought 2,000 shares of the firm’s stock in a transaction on Monday, September 29th. The shares were purchased at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the transaction, the director owned 5,777 shares of the company’s stock, valued at $395,089.03. This represents a 52.95% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 17,975 shares of company stock valued at $1,216,346 over the last three months. 1.98% of the stock is currently owned by corporate insiders.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.